Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560446 | 0.86 | HDAC6 (0.35) | DPP4PREPFAP | |
| SCHEMBL23696191 | 0.85 | HDAC6 (0.37) | DPP4PREPFAP | |
| SCHEMBL23419314 | 0.84 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL21816759 | 0.81 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL3134022 | 0.81 | CHRM1 (0.34) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL13096282 | 0.81 | PRMT6 (0.42) | DPP4PREPFAPCHRNB2CHRNB4 | |
| SCHEMBL23602083 | 0.81 | KDM4E (0.40) | — | |
| SCHEMBL21105937 | 0.81 | KDM4E (0.40) | — | |
| SCHEMBL21105780 | 0.81 | KDM4E (0.40) | — | |
| SCHEMBL24260400 | 0.80 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20200375978-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20170362346-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | CERULEAN PHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20120064071-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110282047-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | DPP4 2370/4885PREP 3200/4885FAP 1552/4885 |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | DPP4 3121/4885PREP 3789/4885FAP 2921/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | DPP4 2370/4885PREP 3200/4885FAP 1552/4885 |
| US-20200375978-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | DPP4 3680/4885PREP 2606/4885FAP 1972/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | DPP4 1397/4885PREP 4022/4885FAP 1971/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | DPP4 2370/4885PREP 3200/4885FAP 1552/4885 |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | DPP4 1567/4885PREP 3270/4885FAP 2717/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | DPP4 1060/4885PREP 1022/4885FAP 1140/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | DPP4 3680/4885PREP 2606/4885FAP 1972/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | DPP4 951/4885PREP 2030/4885FAP 1342/4885 |
| US-20120064071-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | DPP4 3680/4885PREP 2606/4885FAP 1972/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | DPP4 706/4885PREP 948/4885FAP 2824/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | DPP4 3680/4885PREP 2606/4885FAP 1972/4885 |
| US-20110245201-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | DPP4 3680/4885PREP 2606/4885FAP 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.